Equities research analysts predict that Kindred Biosciences Inc (NASDAQ:KIN) will post sales of $1.44 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Kindred Biosciences’ earnings. The lowest sales estimate is $1.30 million and the highest is $1.58 million. The firm is expected to report its next quarterly earnings report on Thursday, March 7th.
On average, analysts expect that Kindred Biosciences will report full year sales of $2.06 million for the current fiscal year, with estimates ranging from $1.90 million to $2.22 million. For the next year, analysts forecast that the business will report sales of $17.34 million, with estimates ranging from $14.40 million to $20.28 million. Zacks’ sales averages are an average based on a survey of analysts that follow Kindred Biosciences.
Kindred Biosciences (NASDAQ:KIN) last released its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.01. The business had revenue of $0.64 million during the quarter.
In other Kindred Biosciences news, CEO Richard Chin sold 40,000 shares of the business’s stock in a transaction on Thursday, November 1st. The shares were sold at an average price of $14.68, for a total transaction of $587,200.00. Following the sale, the chief executive officer now owns 1,986,071 shares of the company’s stock, valued at $29,155,522.28. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Raymond Townsend sold 3,000 shares of the business’s stock in a transaction on Wednesday, September 26th. The stock was sold at an average price of $13.32, for a total transaction of $39,960.00. Following the sale, the director now directly owns 27,813 shares in the company, valued at approximately $370,469.16. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 123,000 shares of company stock valued at $1,689,560. Company insiders own 15.96% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of KIN. Trexquant Investment LP bought a new stake in shares of Kindred Biosciences during the second quarter worth $235,000. Schwab Charles Investment Management Inc. grew its stake in shares of Kindred Biosciences by 35.3% in the second quarter. Schwab Charles Investment Management Inc. now owns 56,979 shares of the biopharmaceutical company’s stock worth $607,000 after purchasing an additional 14,879 shares during the last quarter. BlackRock Inc. grew its stake in shares of Kindred Biosciences by 20.1% in the second quarter. BlackRock Inc. now owns 1,325,147 shares of the biopharmaceutical company’s stock worth $14,114,000 after purchasing an additional 221,578 shares during the last quarter. Ariel Investments LLC grew its stake in shares of Kindred Biosciences by 25.9% in the second quarter. Ariel Investments LLC now owns 2,218,612 shares of the biopharmaceutical company’s stock worth $23,628,000 after purchasing an additional 456,783 shares during the last quarter. Finally, Citadel Advisors LLC bought a new stake in shares of Kindred Biosciences in the second quarter worth $218,000. 66.43% of the stock is currently owned by hedge funds and other institutional investors.
KIN traded down $0.39 during trading on Tuesday, hitting $12.16. 89,701 shares of the stock traded hands, compared to its average volume of 114,856. Kindred Biosciences has a twelve month low of $7.55 and a twelve month high of $15.75. The company has a market cap of $412.38 million, a P/E ratio of -9.89 and a beta of 0.23.
About Kindred Biosciences
Kindred Biosciences, Inc, a biopharmaceutical company, focuses on the development of therapies for pets. The company's product pipeline includes small molecules and biologics for a range of indications in dogs, cats, and horses. Its lead product candidates comprise Zimeta, a dipyrone injection for the control of pyrexia (fever) in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.
Featured Story: What is an SEC Filing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.